By: IPP Bureau
Last updated : September 27, 2025 9:49 am
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Moderna announced that the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK has officially opened.
The MITC will now produce British-made mRNA respiratory vaccines for the UK public to support the National Health Service (NHS) seasonal vaccination programs.
Beyond respiratory diseases, the MITC will also support research into the potential of mRNA science in areas such as cancer, rare diseases and immune disorders.
"The opening of the Moderna Innovation and Technology Centre marks the first facility in the UK to manufacture an onshore supply of mRNA vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our strategic partnership with the UK has already delivered more than 20 clinical trials across 110 sites nationwide, making Moderna the largest commercial sponsor of trials in the country. Together, we successfully delivered this vision from concept to operational readiness in under two years. This latest milestone underscores the UK's commitment to improving health security, both against global health emergencies and ongoing seasonal respiratory threats."
The site can produce up to 100 million mRNA vaccine doses per year, with the capacity to increase to 250 million in the event of a pandemic. The Clinical R&D facility at the MITC also includes laboratories that will analyze samples from Moderna's clinical trials globally.
The MITC is part of a global network of advanced manufacturing hubs, alongside facilities in Australia and Canada that collectively strengthen pandemic readiness by maximizing geographic coverage and minimizing response times.